Cooperative group trials in pediatric oncology: The surgeon's role

Journal of Pediatric Surgery

Volumn 48, Issue 1, 2013, Pages 1-13

  Shamberger, Robert C ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Children's Cancer Study Group; Cooperative group trials; Ewing's sarcoma; Intergroup Rhabdomyosarcoma Study; National Wilms Tumor Study Group; Neuroblastoma; Osteosarcoma; Pediatric Oncology Group; Rhabdomyosarcoma; Wilms tumor

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

CANCER INCIDENCE; CANCER RADIOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL (TOPIC); COOPERATION; EWING SARCOMA; FETUS ECHOGRAPHY; FOLLOW UP; GERM CELL TUMOR; HEALTH SURVEY; HEPATOBLASTOMA; HUMAN; NEPHROBLASTOMA; NEUROBLASTOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHABDOMYOSARCOMA; SURGEON;

GENERAL SURGERY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MEDICAL ONCOLOGY; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; PEDIATRICS; PHYSICIAN'S ROLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 84872377293     PISSN: 00223468     EISSN: 15315037     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2012.10.068     Document Type: Review

References (105)

1. J. Wolff History of pediatric oncology Pediatr Hematol Oncol 8 1991 89 91
2. A. Gilman, and F. Philips The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides Science 103 1946 409 415
3. J. Burchenal, R. Lester, and J. Riley Effect of certain nitrogen mustards and carbamates on transmitted mouse, leukemia Cancer 1948 399 412
4. L. Goodman, M. Wintrobe, and W. Dameshek Nitrogen mustard therapy JAMA 132 1946 126 132
5. S. Farber, L. Diamond, and R. Mercer Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (adminopterin) N Engl J Med 238 1948 787 793
6. O. Pearson, and L. Eliel Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias JAMA 144 1950 1349 1353
7. S. Farber, G.J. D'Angio, and A. Evans Clinical studies of actinomycin D with special reference to Wilms' tumor in children Ann N Y Acad Sci 89 1960 421 425
8. S. Farber, R. Toch, and E. Sears Advances in chemotherapy of cancer in man Adv Cancer Res 4 1956 1 71
9. W. Sutow Vincristine (Leurocristine) sulfate in the treatment of children with metastatic Wilms' tumor Pediatry 32 1963 880 887
10. M.C. O'Leary, M. Krailo, and J. Anderson Progress in childhood cancer: 50 years of research collaboration. A report from the Children's Oncology Group Semin Oncol 35 2008 484 493
11. R. Siegel, D. Naishadham, and J. Ahmedin Cancer statistics Cancer J Clin 62 2012 10 29
12. W. Crist, and L. Kun Common solid tumors of childhood N Engl J Med 324 1991 461 471
13. W. Al-Refaie, S. Vickers, and W. Zhong Cancer trials versus the real world in the United States Ann Surg 254 2011 438 443
14. L. Liu, M. Krailo, and G. Reaman Childhood cancer patients' access to cooperative group cancer programs Cancer 97 2003 1339 1345
15. R. Heyn, C. Brubaker, and J. Burchenal The comparison of 6-Mercaptopurine with the combination of 6-metcaptopurine and azaserine in the treatment of acute leukemia in children: results of a cooperative study Blood 15 1960 350 359
16. J. Wolff, W. Krivit, and J. Newton Single versus multiple dose dactinomycin therapy of Wilms' tumor: a controlled cooperative study conducted by the Children's Cancer Study Group N Engl J Med 279 1968 290 294
17. Hays D. Personal communication.
18. Lawrence W. Personal communication.
19. Ternberg J. Personal communication.
20. D'Angio G. Personal communication.
21. Othersen J, HB: Personal communication.
22. A. Meadows, S. Kramer, and R. Hopson Survival in childhood acute lymphocytic leukemia: effect of protocol and place of treatment Cancer Invest 1 1983 49 55
23. S. Kramer, A. Meadows, and G. Pastore Influence of place of treatment on diagnosis, treatment and survival in three pediatric solid tumors J Clin Oncol 2 1984 917 923
24. C. Stiller, and G. Draper Treatment center size, entry to trials and survival in acute lymphoblastic leukemia Arch Dis Child 65 1989 657 661
25. J. Wagner, I. Dingeldein-Bettler, and W. Betchthold Childhood NHL in Switzerland: incidence and survival of 120 study and 42 non-study patients Med Pediatr Oncol 24 1995 281 286
26. J. Lantos The "inclusion benefit" in clinical trials J Pediatr 134 1999 130 131
27. J. Gutierrez, M. Cheung, and Z. Ying Does Children's Oncology Group Hospital membership improve survival for patients with neuroblastoma or Wilms tumor? Pediatr Blood Cancer 55 2010 621 628
28. http://officeofbudget.od.nih.gov/spending-hist.html S.
29. Smith M. Personal communication.
30. J. Beckwith, and N. Palmer Histopathology and prognosis of Wilms tumor: results from the first National Wilms' Tumor Study Cancer 41 1978 1937 1948
31. M. Schwab, J. Ellison, and M. Busch Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma Proc Natl Acad Sci 81 1984 4940 4944
32. R. Seeger, G. Brodeur, and H. Sather Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas N Eng J Med 313 1985 1111 1116
33. M. Schmidt, J.N. Lukens, and R.C. Seeger Biologic factors determine prognosis in infants with stage IV neuroblastoma: a Prospective Children's Cancer Group Study J Clin Oncol 18 2000 1260 1268
34. A. Look, F. Hayes, and R. Nitschke Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma N Eng J Med 311 1984 231 235
35. S. Taylor, and J. Locker A comparative analysis of nuclear DNA content and N-myc gene amplification in neuroblastoma Cancer 65 1990 1360 1366
36. P. Grundy, P. Telzerow, and N. Breslow Loss of hertozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome Cancer Res 54 1994 2331 2333
37. E. Davicioni, F. Finckenstein, and V. Shahbazian Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas Cancer Res 66 2006 6936 6946
38. E. Davicioni, M. Anderson, and F. Finckenstein Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group Am J Pathol 174 2009 550 564
39. G.J. D'Angio, A.E. Evans, and N. Breslow The treatment of Wilms' tumor: results of the National Wilms' Tumor Study Cancer 38 1976 633 646
40. G.J. D'Angio, A. Evans, and N. Breslow The treatment of Wilms' tumor: results of the second National Wilms' Tumor Study Cancer 47 1981 2302 2311
41. G.J. D'Angio, N. Breslow, and J.B. Beckwith Treatment of Wilms' tumor. Results of the third National Wilms' Tumor Study Cancer 64 1989 349 360
42. D.M. Green, N.E. Breslow, and J.B. Beckwith Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group J Clin Oncol 16 1998 3744 3751
43. D. Green, N. Breslow, and I. Evans Relationship between dose schedule and charges for treatment on National Wilms' Tumor Study-4. A report from the National Wilms' Tumor Study Group J Natl Cancer Inst Monogr 19 1995 21 25
44. P.E. Grundy, N. Breslow, and S. Li Loss of heterogosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor. A report from the National Wilms Tumor Study Group J Clin Oncol 23 2005 7312 7321
45. M. Garcia, E.C. Douglass, and J.V. Schlosser Classification and prognosis in Wilms' tumor Radiology 80 1963 574 580
46. J.R. Cassady, M. Tefft, and R.M. Filler Considerations in the radiation therapy of Wilms' tumor Cancer 32 1973 598 608
47. D.M. Green, and N. Jaffe The role of chemotherapy in the treatment of Wilms' tumor Cancer 44 1979 52 57
48. D.M. Green, N.E. Breslow, and J.B. Beckwith Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study J Clin Oncol 11 1993 91 95
49. D.M. Green, N. Breslow, and J.B. Beckwith Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group J Clin Oncol 19 2001 3719 3724
50. Shamberger RC, Anderson J, Breslow NJ, et al. Long-term outcomes of infants with very low risk Wilms tumor treated with surgery alone on National Wilms Tumor Study-5. Ann Surg 2010;251(3):555-558.
51. H.B. Othersen Jr., A. DeLorimer, and E. Hrabovsky Surgical evaluation of lymph node metastases in Wilms tumor J Pediatr Surg 25 1990 330 331
52. R.C. Shamberger, K.A. Guthrie, and M.L. Ritchey Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study-4 Ann Surg 229 1999 292 297
53. M.L. Ritchey, R.C. Shamberger, and T. Hamilton Fate of bilateral renal lesions missed on preoperative imaging: a report from the National Wilms Tumor Study Group J Urol 174 2005 1519 1521
54. G. Brodeur, F. Hayes, and A. Green Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients Cancer Res 47 1987 4248 4254
55. K.K. Matthay, H.N. Sather, and R.C. Seeger Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy J Clin Oncol 7 1989 236 244
56. C.S. Alvarado, W.B. London, and A.T. Look Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study J Pediatr Hematol Oncol 22 2000 197 205
57. R. Nitschke, E.I. Smith, and S. Shochat Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study J Clin Oncol 6 1988 1271 1279
58. D.R. Strother, W.B. London, and M.L. Schmidt Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group Study P9641 J Clin Oncol 30 15 2012 1842 1848 [Epub 2012 Apr 23]
59. D. Baker, M. Schmidt, and S.L. Cohn Outcome after reduced chemotherapy for intermediate-risk neuroblastoma N Eng J Med 363 2010 1313 1323
60. K. Matthay, J. Villablanca, and R.C. Seeger Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-CIS-retinoic acid N Eng J Med 341 1999 1165 1173
61. E.S. Adkins, R. Sawin, and R.B. Gerbing Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study J Pediatr Surg 39 2004 931 936
62. T.C. Ho, J.A. Estroff, and H. Kozakewich Prenatal detection of neuroblastoma: a ten-year experience from the Dana Farber Cancer Institute and Children's Hospital Pediatrics 92 1993 358 364
63. S. Acharya, S. Jayabose, and S. Kogan Prenatally diagnosed neuroblastoma Cancer 80 1997 304 310
64. R.W. Jennings, M. LaQuaglia, and K. Leong Fetal neuroblastoma: prenatal diagnosis and natural history J Pediatr Surg 28 1993 1168 1174
65. L.O. Holgersen, S. Subramanian, and M. Kirpekar Spontaneous resolution of antenatally diagnosed adrenal masses J Pediatr Surg 31 1996 153 155
66. M.L. Richards, A.E. Gundersen, and M.S. Williams Cystic neuroblastoma of infancy J Pediatr Surg 30 1995 1354 1357
67. P.W. Kozakewich, A. Perez-Atayde, and M.J. Donovan Cystic neuroblastoma: emphasis on gene expression, morphology, and pathogenesis Pediatr Devel Pathol 1 1998 17 28
68. S.B. Murphy, S.L. Cohn, and A.W. Craft Do children benefit from mass screening for neuroblastoma? Lancet 337 1991 344 346
69. W.G. Woods, R. Tuchman, and L.L. Robison Population-based study of the usefulness of screening for neuroblastoma Lancet 348 1996 1682 1687
70. K. Ishimoto, N. Kiyokawa, and H. Fujita Problems of mass screening for neuroblastoma: analysis of false-negative cases J Pediatr Surg 25 1990 398 401
71. W. Woods, B. Lemieux, and M. Tuchman Neuroblastoma represents district clinical-biologic entities: a review and perspective from the Quebec Neuroblastoma Screening Project Pediatr 89 1992 114 118
72. Y. Hachitanda, K. Ishimoto, and J. Hata One hundred neuroblastomas detected through a mass screening system in Japan Cancer 74 1994 3223 3226
73. S. Suita, Y. Naisen, and Y. Sera Mass screening for neuroblastoma: Quo Vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu Area of Japan J Ped Surg 31 1996 555 558
74. K. Yamamoto, R. Hanada, and A. Kikuchi Spontaneous regression of localized neuroblastoma detected by mass screening J Clin Oncol 16 1998 1265 1269
75. J. Nuchtern, W. London, and C. Barnewolt A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group Study Ann Surg 256 2012 573 580
76. R.C. Shamberger, E.I. Smith, and V.V. Joshi The risk of nephrectomy during local control in abdominal neuroblastoma J Pediatr Surg 33 1998 161 164
77. H. Katzenstein, L.C. Bowman, and G.M. Brodeur Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the Pediatric Oncology Group experience - a Pediatric Oncology Group Study J Clin Oncol 16 1998 2007 2017
78. H.M. Maurer, M. Beltangady, and E.A. Gehan The Intergroup Rhabdomyosarcoma Study-I: a final report Cancer 61 1988 209 220
79. H.M. Maurer, E.A. Gehan, and M. Beltangady The Intergroup Rhabdomyosarcoma Study-II Cancer 71 1993 1904 1922
80. W.M. Crist, L. Garnsey, and S. Beltangady Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II J Clin Oncol 8 1990 443 452
81. W. Crist, E.A. Gehan, and A.H. Ragab The Third Intergroup Rhabdomyosarcoma Study J Clin Oncol 13 1995 610 630
82. W.M. Crist, J.R. Anderson, and J.L. Meza Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease J Clin Oncol 19 2001 3091 3102
83. S.S. Donaldson, J. Meza, and J.C. Breneman Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma: a report from the IRSG Int J Radiat Biol Phys 51 2001 718 728
84. D.A. Rodeberg, J.A. Stoner, and A. Hayes-Jordan Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the Children's Oncology Group J Clin Oncol 27 2009 3705 3711
85. W. Lawrence, D.M. Hays, and R. Heyn Surgical lessons from the Intergroup Rhabdomyosarcoma Study (IRS) pertaining to extremity tumors World J Surg 12 1988 676 684
86. R.J. Andrassy, C.A. Corpron, and D. Hays Extremity sarcomas: an analysis of prognostic factors from the Intergroup Rhabdomyosarcoma Study III J Pediatr Surg 31 1996 191 196
87. E.S. Wiener, W. Lawrence, and D. Hays Retroperitoneal node biopsy in paratesticular rhabdomyosarcoma J Pediatr Surg 29 1994 171 177 [discussion 178]
88. E.S. Wiener, J.R. Anderson, and J. Ojimbam Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg 10 2001 146 152
89. C.A.S. Arndt, S. Donaldson, and J.R. Anderson What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract? Cancer 91 2001 2454 2468
90. H.E. Grier, M.D. Krailo, and N.J. Tarbell Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of the bone N Eng J Med 348 2003 694 701
91. J.A. Ortega, E.C. Douglass, and J.H. Feusner Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Oncology Cancer Group and the Pediatric Oncology Group J Clin Oncol 18 2000 2665 2675
92. L. Granowetter, R.B. Womer, and M. Devidas Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study J Clin Oncol 27 2009 2536 2541
93. R.B. Womer, D.C. West, and M.D. Krailo Randomized comparison of every two week v every three week chemotherapy in Ewing sarcoma family tumors J Clin Oncol 26 2008 1054
94. R.C. Shamberger, M.P. LaQuaglia, and M.C. Gebhardt Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy Ann Surg 238 2003 563 567 [discussion 567-568]
95. J. Ewing Diffuse endothelioma of bone Proc N Y Patholo Soc 21 1921 17 24
96. J. Ewing A review and classification of bone sarcomas Arch Surg 4 1922 485 533
97. D.J. Pritchard, D.C. Dahlin, and R.T. Dauphine Ewing's sarcoma: a clinicopathological and statistical analysis of patients surviving five years or longer J Bone Joint Surg 57 1975 10 16
98. A.P. Brown, J.A. Fixsen, and P.N. Plowman Local control of Ewing's sarcoma: an analysis of 67 patients Br J Radiol 60 1987 261 268
99. P.R.M. Thomas, M.A. Foulkes, and L.A. Gilula Primary Ewing's sarcoma of the ribs: a report from the Intergroup Ewing's Sarcoma Study Cancer 51 1983 1021 1027
100. V. Gobel, H. Jurgens, and G. Etspuler Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents J Cancer Res Clin Oncol 113 1987 187 191
101. DuBois SG, Krailo M, Gebhardt MC, et al. Evaluation of local control strategies in patients with localized Ewing Sarcoma of bone: a report from the Children's Oncology Group. ASCO Abstract 9537.
102. G. Heinze, and P. Juni An overview of the objectives of and the approaches to propensity score analyses Eur Heart J 32 2011 174 1708
103. A.L. Frazier, M. Schlater, and J. Cullen Stage I ovarian germ cell tumors: outcome of a watch and wait strategy Presentation at the 42nd Annual Congress of the International Society of Paediatric Oncology (SIOP), Boston, MA 2010
104. F. Rescorla, D. Billmire, and C.J. Stolar The effect of cisplatin dose and surgical resection in children with malignant germ cell tumors at the sacrococcygeal region: a Pediatric Intergroup Trial (POG 9049/CCG 8882) J Pediatr Surg 36 2001 12 17
105. M.A. Smith, N.L. Seibel, and S.F. Altekruse Outcomes for children and adolescents with cancer: challenges for the twenty-first century J Clin Oncol 28 2010 2625 2634